Fig. 4: TLR7/8 agonist prodrug orchestrates cDC1s to invigorate CD8⁺ T cell responses through type I IFN signal.

a Six to 8 weeks old female C57BL/6 mice (n = 6 mice) were inoculated with 5 × 10⁵ MC38 cells. Tumor-bearing mice were treated with PBS or radiotherapy-activated O-IMDQ on days 10 and 13 (6 Gy). The mice were sacrificed, and tumor tissues were collected 72 h after the second injection. CD45⁺CD3⁺CD8⁺ T cells were sorted for RNA-seq. Gene expression levels were shown. b The schematic of radiotherapy-activated TLR7/8 agonist treatment. c MC38 tumor-bearing mice (6–8 weeks old female C57BL/6J mice, n = 6 mice) were i.v. treated with O-IMDQ and/or 6 Gy radiation on days 13 and 16. 500 μg anti-IFNαR Ab was injected before treatment. The mice were sacrificed, and tumor tissues were collected 72 h after the last treatment. CD45⁺MHC II⁺CD11c⁺ DCs were determined by flow cytometry. d CD86 expression on DCs was determined by flow cytometry. e The antigen presentation function of DCs was determined by flow cytometry. f CD45⁺CD8⁺ T cells were determined by flow cytometry. g Antigen-specific CD8⁺ T cells were determined by flow cytometry. h Ki67 was determined by flow cytometry. i IFNγ was determined by flow cytometry. j GrzmB was determined by flow cytometry. Data were shown as mean ± SEM and are representative of at least three independent experiments. Statistical analysis was performed using Student’s two-tailed unpaired t-test. Exact P value has been provided in the figures. N numbers define the biological replicates. Source data are provided as a Source Data file.